Investors: Janus Henderson Investors, Adage Capital Management, Franklin Templeton, Invus, Marshall Wace, 4BIO Capital, Deerfield Management, MRL Ventures Fund, Norwest, Novo Holdings A/S, Platanus
Gene therapy company RayTx closed oversubscribed $125M Series B to advance clinical-stage programs through trials.